Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

ifferences,

if any, in the rates of valvulopathy (as defined by the Food and Drug

Administration, or FDA) in patients treated with lorcaserin and in the

control group did not meet the ESMB's predetermined stopping criteria.

o Announced the initiation of a Phase 1 clinical trial of a second

generation oral niacin receptor agonist intended for the treatment of

atherosclerosis in partnership with Merck & Co., Inc.

o Entered into strategic agreements with Siegfried Ltd primarily related

to the manufacturing of lorcaserin for Arena's planned New Drug

Application submission to the FDA and for commercialization of

lorcaserin after regulatory marketing approval. The agreements include

the purchase of certain drug product manufacturing and packaging

facility assets, including fixtures, equipment, other personal property

and real estate assets, located in Zofingen, Switzerland.

o Reported positive Phase 1a clinical trial results of APD791, Arena's

oral, internally discovered drug candidate intended for the treatment of

arterial thrombosis, and initiated a Phase 1b clinical trial to further

evaluate this drug candidate.

o Announced that initial clinical trial results for APD668, an oral drug

candidate discovered by Arena and being investigated for the treatment

of type 2 diabetes in partnership with Ortho-McNeil Pharmaceutical,

Inc., suggest that the Glucose-Dependent Insulinotropic Receptor, or

GDIR, improves glucose control in patients with type 2 diabetes. Based

on the data from those studies, Ortho-McNeil put APD668 on hold and

advanced a potentially more potent Arena-discovered GDIR agonist into

preclinical development.

Scheduled Earnings Call

Arena will host both a conference call and webcast to discuss the first quarter 2008 financial results and to provide a corporat
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... at the University of Surrey have discovered how the ... body,s clock genes. , The new study, published today ... this clock activity in turn regulates the cycle of ... also discovered that the local biological clock and its ... of the clock in bladder physiology and ageing. ...
(Date:8/22/2014)... (August 22nd), in the scientific journal PLoS ... establish the effect of serotonin on sensitivity to ... optical techniques., "Serotonin is a small molecule known ... brain functions, from the control of sleep and ... This neurotransmitter is also popularly thought to contribute ...
(Date:8/22/2014)... direct observations of how facets form and develop ... sophisticated and effective nanocrystal design and reveal that ... growth breaks down at the nanoscale. , Researchers ... Berkeley National Laboratory (Berkeley Lab) used highly sophisticated ... camera to capture the physical mechanisms that ...
(Date:8/22/2014)... particles are intensively investigated for application as ... agents and components in photonics and molecular ... fundamental for understanding physical and chemical properties, ... University, USA, have demonstrated that high-resolution electron ... three-dimensional structure in which all gold atoms ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2From happiness to pain: Understanding serotonin's function 2Shaping the future of nanocrystals 2Shaping the future of nanocrystals 3Shaping the future of nanocrystals 4A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy 2
... Elizabeth P. Roquemore, Sam Murphy, *Stephen ... Swinburne , , ... 9NA England, , ... throughput imaging systems, analysis algorithms and associated,cellular assays have begun to be used ...
... , Key words: ... LC-MS/MS • DeCyder MS • differential analysis, ... was used in conjunction with tandem mass spectrometry (MS/MS) to separate ... tree, Olea europaea . DeCyder™ MS Differential Analysis Software (DeCyder ...
... Karlsson, and H. Lindgren , ... Sweden , , ... columns prepacked with Ni Sepharose 6 Fast Flow without the need for a ... the highest available on the market, and separations can be completed in as ...
Cached Biology Technology:Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 2Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 3Is Z' factor the best assessment for the quality of cellular assays delivering higher content? 4Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 2Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 3Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 4Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 5Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 6Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 7Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 8Detection, identification, and quantitation of an olive allergen using Ettan MDLC, MS/MS, and DeCyder MS 9New gravity-flow column gives faster and simpler purification of histidine-tagged proteins 2New gravity-flow column gives faster and simpler purification of histidine-tagged proteins 3New gravity-flow column gives faster and simpler purification of histidine-tagged proteins 4
(Date:8/21/2014)... 18-22, 2014 , WHERE: , San Diego ... CA 92101 , WHAT: , Invited and ... latest research in human genetics. Examples of sessions ... on rare genetic variants in health and disease, ... sun sensitivity (Saturday, Oct. 18, 5:30-7:30 pm) , ...
(Date:8/21/2014)... tube connectors, designed by an international standards process, will ... According to an invited review published in the OnlineFirst ... NCP ), the official journal of the American Society ... will greatly reduce the occurrence of misconnection that can ... connectors, which are used to join medical devices, components, ...
(Date:8/21/2014)... has successfully replicated one of the crucial steps in ... sunlight which could manufacture hydrogen as a fuel. , ... an exciting prospect to use them to create hydrogen, ... Hingorani, from the ARC Centre of Excellence for Translational ... Hydrogen offers potential as a zero-carbon replacement for petroleum ...
Breaking Biology News(10 mins):American Society of Human Genetics 2014 Annual Meeting 2New feeding tube connectors will improve patient safety 2Water and sunlight the formula for sustainable fuel 2
... marker for Alzheimer,s disease rises and falls in the spinal ... researchers at Washington University School of Medicine in St. Louis ... young people and reinforces a link between increased Alzheimer,s risk ... The brain,s relative inactivity during sleep may provide an ...
... NEW YORK (Sept. 26, 2011) -- The National Institutes ... Research Project (T-R01) Award to fund research into risk factors ... area of the affected baby,s spine or brain is not ... Margaret Elizabeth Ross and Dr. Christopher E. Mason at Weill ...
... Rochelle, NY, September 26, 2011Magnetic resonance tractography (MRT) ... human brain anatomy and, as MRT methods and ... and illuminating information on brain activity and connectivity. ... this technology is explored in a forward-looking review ...
Cached Biology News:Marker for Alzheimer's disease rises during day and falls with sleep 2Marker for Alzheimer's disease rises during day and falls with sleep 3NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 2NIH awards $5.5 million grant to Weill Cornell for research into preventing spina bifida 3
...
... Endogenous potent vasoconstrictor peptide. Displays selectivity ... vascular tonus. ET-1, ET-2, and ET-3 are ... ET-2 and ET-3 are similar to ET-1, ... acids, respectively. All three isopeptides produce strong ...
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... include subcloning of gene in baculoviral ... isolation and plaque purification of ten ... stock for one clone, protein expression ... cell culture. Expected yield and timeline: ...
Biology Products: